February 22 – 24, 2016 

Boston, USA

Speakers

Expand/Collapse

Spyros Papapetropoulos
Vice President & Global Head of Development Neurodegenerative Diseases
Teva Pharmaceuticals

Spyros is a recognized researcher and global pharmaceutical executive with experience in drug development, life cycle management, medical affairs and digital health. Spyros is currently Vice President and Global Head of Neurodegeneration at TEVA. Prior joining TEVA he was the Global Program Lead responsible for a portfolio of development programs in neurodegeneration, migraine, neuroinflammation, psychiatry and rare diseases at Pfizer’s Neuroscience Research Unit. Before Pfizer, he served as Therapeutic Area Head, Neurosciences, Allergan Global Medical Affairs responsible for peri- and post approval neuroscience programs and as Global Clinical Lead/Clinical Development, Alzheimer’s and Parkinson’s disease at Biogen IDEC. Spyros has managed teams that consistently met and exceeded goals leading to successful regulatory filings, product launches, “beyond the pill” strategies and growing portfolios. He has led and completed multi-billion dollar business development efforts and corporate partnerships with profit and non-profit organizations. Spyros has proven people skills, is a strong leader focused on innovation, organizational excellence and efficiency.

Spyros is a board-certified Neurologist and a Movement Disorders specialist trained at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. He received his PhD on the genetics of Parkinson’s disease.

Spyros started his career in academic neurology. He was appointed faculty at the University of Miami, Miller School of Medicine where he held positions of increasing responsibility. Before joining industry he was Associate Professor of Neurology and Director, Research Programs at the Division of Movement Disorders, Department of Neurology. As an academic researcher, Spyros conducted award-winning clinical and translational research in neurodegenerative disease and Movement Disorders. He has received funding from multiple sources including the US National Institutes of Health, the Muscular Dystrophy Association and the Alzheimer’s Association. His primary academic interests are in the space of technology and digital health. Spyros is currently chairing the newly formed International Parkinson’s Disease and Movement Disorders Society’s (IPMDS) Taskforce on Technology.

Day Two

Wednesday 24th February, 2015

11:00 | Harnessing the Full Potential of Big Data & Digital Health for More Efficient Clinical Trials

Sam Agus
Senior Director
Lundbeck

Day Two

Wednesday 24th February, 2015

09:40 | Panel Discussion: Revolutionizing Clinical Trial Design to Improve the Progression of Neurodegenerative Therapeutics Through to the Clinic

09:20 | Delayed-Start Clinical Studies: Reflections & Lessons from the ADAGIO Study

Johannes Tauscher
Vice President & Head of Clinical Imaging and CNS Experimental Medicine
Takeda

Johannes Tauscher currently serves as Vice President for CNS Experimental Medicine / Early Clinical Development at Takeda Pharmaceuticals Intl. based in Deerfield, IL. Dr Tauscher obtained his medical degree at University Vienna, Austria, and underwent subsequent specialty training in Psychiatry and Neurology at the Medical University of Vienna, Austria, and the Clarke Institute of Psychiatry in Toronto, Ontario. Additionally he trained in Molecular Neuroimaging at the Vivian Rakoff PET Centre, Univ. of Toronto. In 2001 he was appointed Associate Professor of Psychiatry with the Medical University of Vienna, and served as Head of the Outpatients Clinic of the Dept. of General Psychiatry, where he also practiced as a Psychiatrist and Neurologist in private office.

In 2004, Dr Tauscher moved to the US as a Sr. Clinical Research Physician with Eli Lilly and Co. in Indianapolis, IN, responsible for the clinical development of novel psychiatric treatments. Dr. Tauscher was promoted to Head of the Translational Imaging Group in 2006, leading a group of physician/scientists and operational staff, implementing Lilly’s Imaging Biomarker Strategy through a world-wide network of research partners.

Prior to joining the Pharmaceutical Industry, Dr Tauscher’s major research endeavors comprised of imaging studies in psychiatric disorders, and to use these image modalities to elucidate the mechanism of action of psychotropic drugs. Dr Tauscher published more than 70 articles in peer reviewed scientific journals and 5 chapters in standard textbooks. He received international recognition for his academic accomplishments (Rafaelsen Fellowship Award, CINP 1998; Young Investigator Award, ICOSR 2001; Young Minds in CNS Award, APA 2001; Memorial Travel Award, ACNP 2002; Independent Investigator Award, NARSAD 2002), and serves as reviewer for a number of scientific journals.

Day Two

Wednesday 24th February, 2015

09:40 | Panel Discussion: Revolutionizing Clinical Trial Design to Improve the Progression of Neurodegenerative Therapeutics Through to the Clinic

09:00 | Applying Translational Research to Early Clinical Development: Improving the Progression of Candidates for Neurodegeneration

Jang-Ho Cha
Global Head Translational Medicine Neuroscience
Novartis

Kuldip Dave
Director Research Programs
Michael J Fox Foundation

Dr. Dave earned an undergraduate degree in biology from Rutgers University and a PhD in Pharmacology & Physiology from the MCP-Hahnemann University. His thesis work focused on serotonergic regulation of motor function and learning and memory. He completed his postdoctoral fellowship at a small biotechnology firm Adolor Corporation investigating opioid-receptor regulation of pain and inflammation pathways. Kuldip went on to work for the pharmaceutical company Wyeth managing programs within the Women's Health Department focusing on the hormonal regulation of mood and sexual disorders. At the Michael J. Fox Foundation, Kuldip serves as Director, Research Programs, and stays closely linked to the Parkinson's community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson's disease. This ensures that MJFF priorities reflect and best serve the ultimate needs of patients. Kuldip regularly meets with academic and industry scientists around the world to identify promising proposals to support, providing troubleshooting and ongoing management of projects as they go forward. He supports the Foundation's priority interest in alpha-synuclein, an important protein linked genetically and pathologically to Parkinson's disease. He also oversees the emerging targets portfolio to identify and validate novel targets for PD.

Day One

Tuesday 23rd February, 2016

15:00 | Characterization, Comparison, & Cross-Validation of Alpha- Synuclein Preclinical Models of Parkinson’s Disease

Sophie Parmentier- Batteur
Director Neuroscience Early Discovery
Merck

Sophie Parmentier-Batteur received her Pharm.D degree from University of Lille, France and her Ph.D. degree in Neuropharmacology from the University René Descartes of Paris, where she studied the role of the inflammatory response in ischemic stroke and other neurological disorders. Following her graduate studies, she completed two postdoctoral trainings studying the mechanisms of neuroprotection and neurogenesis against stroke at UCSF and at the Buck Institute for Research in aging, Novato, CA. In 2005, she joined the Neuroscience team of Merck Research Laboratories. A key role for Sophie since 2005 has been to lead teams in the translation of basic research findings into drug candidates in the early development pipeline. In addition to leading several drug discovery projects for the treatment of stroke, schizophrenia, and Alzheimer’s Disease, Sophie has implemented new capabilities aimed at improving the validation of novel targets including models of iPSC-derived human neurons and High Content Imaging System. She currently is a Director leading the Early Discovery Neuroscience Group in West point, PA, and co-chairing the Neuroscience Early Discovery Unit core team.

Day One

Tuesday 23rd February, 2016

16:50 | Panel Discussion: Debating the Relevance of the Animal Model in the Field of Neurodegeneration

16:30 | New Ways to Stimulate Drug Discovery in Neuroscience Using Human Derived Cells for Modeling Neurodegenerative Diseases

Richard Wyse
Director of Research and Development
Cure Parkinson’s Trust

Dr Richard Wyse is the Director of Research and Development at The Cure Parkinson’s Trust. He was senior lecturer in pediatric cardiology at Great Ormond Street Hospital, London for more than 20 years, and has also worked extensively at the Brompton and Hammersmith Hospitals in London, and in the pharmaceutical and medical devices industries in London and Philadelphia. For 3 years he was vice-chairman of the Academic Board and Trustee of the Royal Society of Medicine, as well as its President of Medical Genetics. Commercially, he has been Medical Director of two companies in the UK and USA, and has chaired over 30 international pharmaceutical conferences, published 4 industry books (on Pharmacoeconomics and Patient Outcomes), and around 120 academic and clinical research papers in a variety of therapeutic areas. He is currently engaged in worldwide basic and clinical research developing radical new pharmaceutical and regenerative medicine treatments for Parkinson’s disease (PD). These include a major global initiative involving drug repositioning clinical trials conducted in many specialist neurology hospitals around the world to determine and compare the relative patient benefits of a large number of different therapeutics each with compelling biochemical and pharmaceutical rationales for the disease-modifying treatment of PD, and which straddle >60 different biological targets.

Day Two

Wednesday 24th February, 2015

12:00 | Addressing the Therapeutic Landscape in Parkinson’s Disease

09:40 | Panel Discussion: Revolutionizing Clinical Trial Design to Improve the Progression of Neurodegenerative Therapeutics Through to the Clinic

Vaibhav Diwadkar
Associate Professor of Psychiatry & Behavioral Neurosciences
Wayne State University School of Medicine

Dr. Diwadkar is currently Associate Professor of Psychiatry & Behavioral Neurosciences at Wayne State University School of Medicine. He received his B.A. in Psychology and Computer Science from Coe College and his PhD in Psychology and Cognitive Science from Vanderbilt University. Following neuroimaging-related fellowships at Carnegie Mellon University and the University of Pittsburgh, he served on the faculty of the University of Pittsburgh (where he maintains an adjunct appointment) and at Wayne State University where he has been since 2005. He uses vivo neuroimaging to understand brain network mechanisms underlying psychological and physiological processes, having published in the areas of learning, memory, cognition, and sensorimotor function. More recently he has extended the use of fMRI to identify correlates of thermo-regulatory related brain responses.

He has significant clinical neuroimaging interests, particularly in understanding brain network dysfunction underlying psychiatric illness. He has published extensively in the areas of schizophrenia, mood disorders, and borderline personality disorder. A particular area of his interest is in understanding how risk and vulnerability for psychiatric illness impacts brain network function in adolescence, and how network dysfunction in turn increases the risk for psychiatric illness. His research has been supported by the National Institutes of Mental Health, the Children's Research Center of Michigan, the Children’s Hospital of Michigan Foundation, the Prechter World Bipolar Foundation, and the National Alliance for Research on Schizophrenia and Depression.

Day One

Tuesday 23rd February, 2016

10:00 | Incorporating Neuroimaging in Advancing Biomarker Monitoring: Bases & Challenges

Raj Hooli
Instructor in Neurology
Harvard Medical School

Day One

Tuesday 23rd February, 2016

12:30 | Harnessing the Power of Whole Genome Sequencing to Advance Our Understanding of Neurodegenerative Diseases

Rene Anand
Professor, Department of Pharmacology
Ohio State University

Dr. Rene Anand’s research interests lie in neurological disorders, including autism, and the development of therapeutics. Dr. Anand is developing stem cell models of neurodevelopmental (autism, addiction, schizophrenia) and neurodegenerative (AD and PD) diseases to understand how disease susceptibility arises from the interactions of the environment with human gene variants.

He has been nominated as one of the 30 most innovative researchers in autism. He has also recently engineered the first almost complete human brain organoid using stem cells; considered a major breakthrough and a "quantum jump" in the field of human organogenesis.

Dr. Anand earned his BS (Chemistry) from Loyola College, India, M.S. (Chemistry/Chemical Physics) from the Indian Institute of Technology, Chennai, India, and his Ph.D. at The Ohio State University. He did his postdoctoral training at the Salk Institute, San Diego and University of Pennsylvania, Philadelphia.

He held faculty positions at the University of Pennsylvania and Louisiana State University Neuroscience Center and is currently Professor in the Department of Biological Chemistry and Pharmacology at The Ohio State University College of Medicine and Wexner Medical Center. He has served on the grant review panel for Brain Canada, Alzheimer’s Association, NIH, Autism Speaks, California Tobacco-Related Disease Research Program (TRDRP), Hong Kong Research Grants Council, Israel Science Foundation, and American Association for Advancement of Science.

He has served on the External Advisory Board Member, NERT program, Louisiana Tech, External Advisory Board Member for NINDS Human DNA Repository, and Autism Speaks.

Dr. Anand has earned the Lieber Independent Investigator Award from NARSAD as well as the Exceptional, Unconventional Research Enabling Knowledge Accesleration (EUREKA) award from the National Institutes of Health for his research. .

His research has been funded by NIH, Autism Speaks, the Bill and Marci Ingram Family Fund, and the Brain and Behavior Foundation (NARSAD)

Day One

Tuesday 23rd February, 2016

16:50 | Panel Discussion: Debating the Relevance of the Animal Model in the Field of Neurodegeneration

16:10 | Translatable Alternatives to the Animal Model: The Future of Modelling Systems Routed in Stem Cell Technology

Kari Stefansson
CEO, deCODE Genetics Howard Federoff, Vice Chancellor for Health Affairs
and Dean of School of Medicine, University of California Irvine

Day One

Tuesday 23rd February, 2016

14:00 | The Genetics Behind the Functions & Dysfunctions of the Brain

Dan Hutcheson
Former Vice Director – NORD - pRED Strategy & Portfolio
Roche

Day One

Tuesday 23rd February, 2016

17:30 | Chair's Closing Remarks

08:50 | Chair’s Opening Remarks

Day Two

Wednesday 24th February, 2015

16:10 | Chair's Closing Remarks

15:30 | Panel Discussion: The Past, Present & Future in Neurodegenerative Therapeutics • Debating the Amyloid Beta hypothesis: Is Amyloid

09:40 | Panel Discussion: Revolutionizing Clinical Trial Design to Improve the Progression of Neurodegenerative Therapeutics Through to the Clinic

08:50 | Chair’s Opening Remarks

Warren Hirst
Associate Research Fellow Neurodegeneration
Pfizer

Warren Hirst, PhD, is an Associate Research Fellow in the Pfizer Neuroscience Research Unit and leads a group focusing on novel therapeutic strategies for Parkinson’s disease. His research is currently focused on 1) Determining the mechanisms underlying the mutations in LRRK2 and GBA to the pathophysiology of disease, 2) Evaluating whether these enzymes are also affected in PD patients who don’t carry these specific mutations, 3) Developing novel therapeutics: Leading the GBA program and a key member of the LRRK2 kinase inhibitor program. He was previously in the Wyeth Neurodegeneration Research Department, where he led the molecular pharmacology group and worked for GlaxoSmithKline, UK, before this. Dr. Hirst received his B.Sc. and Ph.D from Imperial College, London. He has published over 50 peer-reviewed articles.

Day Two

Wednesday 24th February, 2015

13:30 | How to Apply Our Knowledge of Genetic Drivers in Parkinson’s Disease to Progress the Development of Novel Therapeutics

Greg Stewart
Vice President
Voyager Therapeutics

Day One

Tuesday 23rd February, 2016

14:30 | Scoring a Therapeutic Bulls-Eye with Genetic Medicine Targeted to the CNS

Day Two

Wednesday 24th February, 2015

15:30 | Panel Discussion: The Past, Present & Future in Neurodegenerative Therapeutics • Debating the Amyloid Beta hypothesis: Is Amyloid

Reinhard Gabathuler
Chief Scientist
biOasis Technologies

Dr Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982, and completed postdoctoral studies at the University of Washington, Seattle. Over the years, he has held various research positions at the Swiss Institute for Experimental Cancer Research, Lausanne; the Ludwig Institute for Cancer Research at the Karolinska Institutet, Stockholm, Sweden; and the Biotechnology Laboratory of the University of British Columbia, Vancouver, Canada. His research on new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he become the Vice President of Research. The company was later acquired by BioMarin Pharmaceutical Inc., where Dr Gabathuler assumed the position of Vice President of Brain Research.

Dr Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D; programs, advancing the company’s product ANG1005 to IND application and clinic.

Dr Gabathuler is now involved as Chief Scientist at biOasis Technologies Inc. in the development of new peptide vector, Transcend. He is also the President and CEO of bioMmune Technologies Inc., concerned with the discovery and development of new therapeutics to restore immuno-recognition of tumor cells and to modulation of the activity of the immune system.

Pre Conference Workshops

Tuesday February 22nd, 2016, 2015

14:00 | Unlocking the Unlockable: Targeted Approaches to Crossing the Blood-Brain Barrier

Satish Medicetty
President and CEO
Renovo Neural

Dr. Medicetty is the President and CEO of Renovo Neural Inc. and has built a strong team with efficient operational structure that has contributed to Renovo’s accomplishments to date. Prior to Renovo, Dr. Medicetty was the Director of Stem Cell Research and Lab Operations at NeoStem Inc, where he was instrumental in establishing company’s global R&D; headquarters in Cambridge, MA, and initiating international R&D; operations in China. At NeoStem, he established and managed academic and industry collaborations, and developed protocols to pursue preclinical development of peripheral blood derived adult stem cells. He also worked at Athersys Inc as a Senior Scientist in the division of Regenerative Medicine, where he was actively involved in the development of adult stem cell-based therapies for cardiovascular and neurological diseases. He received a degree (BVSc – equivalent to DVM) in Veterinary Medicine from A.N.G.R.A.University, India. He received a PhD from Kansas State University, where he was part of a stem cell research team that has conducted and published seminal work on characterization of stem cells from umbilical cord matrix and their potential therapeutic applications for Parkinson’s disease. Later, he received his MBA from Weatherhead School of Management, where he specialized in strategic management.

Day One

Tuesday 23rd February, 2016

16:50 | Panel Discussion: Debating the Relevance of the Animal Model in the Field of Neurodegeneration

15:50 | Making Preclinical Models More Translatable to Accelerate New Targets into Clinical Trials

Andrea Edlin
Associate Scientific Director
Genzyme

Day Two

Wednesday 24th February, 2015

15:30 | Panel Discussion: The Past, Present & Future in Neurodegenerative Therapeutics • Debating the Amyloid Beta hypothesis: Is Amyloid

14:00 | Defining the Future of Neurodegenerative Therapeutics: Neuroinflammation & the Immune System

Paul McCracken
Senior Director & Head of Translational Biomedicine
Eisai

Day One

Tuesday 23rd February, 2016

12:00 | Impacting Decisions with Imaging in Neuroscience Drug Discovery & Early Development

Gabriel Vargas
Executive Medical Director, General Medicine, Bone
& Neuroscience Therapeutic Area Head, Early Development, Amgen

Gabriel Vargas, MD, PhD is a board certified psychiatrist and basic scientist with clinical experience in the treatment and management of schizophrenic patients. Gabriel obtained his undergraduate degree cum laude from the University of California at Berkeley where he majored in anthropology & genetics. He received his MD and PhD degrees from the University of California at Irvine and went on to complete a basic science research track residency in Psychiatry at the University of California at San Francisco (UCSF). After both a clinical and research fellowship he was appointed an assistant professor in the Psychiatry Department at UCSF where he spent 3 years leading a research group studying G-protein coupled receptor (GPCR) signaling and trafficking. He has published in the areas of GPCR signaling, membrane trafficking and biomarkers for CNS disorders. After leaving academia in 2006 he spent five years at Roche the last 3 in Basel, Switzerland as head of the CNS Biomarker Group. He is currently at Amgen as Executive Medical Director and Neuroscience Therapeutic Area Head for Early Development.

Day Two

Wednesday 24th February, 2015

11:30 | Mobile Health: Perspectives on Potential Utility in Neuroscience Early Development

John Beaver
Head of Translational Imaging
AbbVie

John Beaver has been with Abbvie since 2012, leading translational imaging across AbbVie’s neuroscience, oncology, immunology and aging-related drug discovery programs. Dr. Beaver has influenced many programs, notably developing translational strategies for early-stage Alzheimer’s disease and multiple sclerosis projects. Prior to joining Abbvie, he was Director of Imaging Technologies at Maccine, Singapore, and a Senior Imaging Scientist at GlaxoSmithKline’s Clinical Imaging Centre, embedded in the Hammersmith Hospital campus of Imperial College, London. Dr. Beaver was an MRC postdoctoral Fellow and earned his doctorate in cognitive and brain sciences at the University of Cambridge, England. He has authored over 31 papers in peer-reviewed journals and has been an invited presenter at many conferences.

Day One

Tuesday 23rd February, 2016

16:50 | Panel Discussion: Debating the Relevance of the Animal Model in the Field of Neurodegeneration

09:00 | Utilizing Neuroimaging to Develop Strategies for Multiple Sclerosis Programs • Identification of neuroinflammatory

Howard Federoff
Vice Chancellor for Health Affairs and Dean of School of Medicine
University of California, Irvine

As Vice Chancellor for Health Affairs and Dean of the School of Medicine at the University of California at Irvine, Dr. Federoff has oversight for the clinical, medical educational, and research missions. His research interests include gene therapy and neurodegenerative diseases. Dr. Federoff has published greater than 250 peer review and invited articles, serves as a reviewer for many journals, and currently serves on the editorial boards of five journals. He has served as Chair of the NIH Recombinant DNA Advisory Committee from 2007-2010.and currently Chairs the Gene Therapy Resource Program for NHLBI.  Previous President of the American Society for Neural Therapy and Repair (2012-2013) and current President of the American Society for Experimental Neurotherapeutics. Dr. Federoff received his MS, PhD, and MD degrees from the Albert Einstein College of Medicine, did his internship, residency, and clinical and research fellowships at Massachusetts General Hospital/Harvard Medical School, practiced medicine at MGH, Albert Einstein and Strong Memorial Hospital at the University of Rochester. He is a Fellow of the AAAS and National Academy of Inventors.  

Day One

Tuesday 23rd February, 2016

09:30 | Improving Diagnostic Capabilities to Earlier Identify Patients Before the Onset of Cognitive Symptoms

Matthew Kennedy
Director, Early Discovery Neuroscience
Merck

Day Two

Wednesday 24th February, 2015

15:30 | Panel Discussion: The Past, Present & Future in Neurodegenerative Therapeutics • Debating the Amyloid Beta hypothesis: Is Amyloid

14:30 | BACE Inhibitors: The Statins of Neurodegeneration?